Repositioning Candidate Details
| Candidate ID: | R0430 |
| Source ID: | DB04854 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Febuxostat |
| Synonyms: | |
| Molecular Formula: | C16H16N2O3S |
| SMILES: | CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N |
| Structure: |
|
| DrugBank Description: | Febuxostat is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management. Febuxostat is not recommended for the treatment of asymptomatic hyperuricemia. Febuxostat is marketed under the trade name Uloric by Takeda Pharmaceuticals America, Inc., and was approved by the FDA in February 2009. |
| CAS Number: | 144060-53-7 |
| Molecular Weight: | 316.375 |
| DrugBank Indication: | For the treatment of hyperuricemia in patients with gout. |
| DrugBank Pharmacology: | Febuxostat (ULORIC) is a novel, xanthine oxidase/dehydrogenase (XO/XDH) inhibitor being developed by Teijin, TAP Pharmaceuticals, and Ipsen for the treatment of gout. The currently available XO inhibitor, allopurinol, has been associated with serious instances of severe hypersensitivity, in some cases leading to fatalities. There is some suggestion that febuxostat is less prone to excacerbate systemic inflammatory events in animal studies. |
| DrugBank MoA: | Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations. |
| Targets: | Xanthine dehydrogenase/oxidase |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|